OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
RAAJ56

Raaj Medisafe India Ltd

Commodity ChemicalsVerified

Raaj Medisafe India Ltd has a debt-to-equity ratio of 2.39, indicating a capital structure that is heavily leveraged relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.16, suggesting it has just enough current assets to cover its current liabilities. However, the company's cash and equivalents amount to only INR 321,130, which is significantly lower than its long-term debt of INR 259,263,440, resulting in a negative net cash position. The company's profitability metrics show a return on equity (ROE) of 6.45% and a return on assets (ROA) of 1.69%. These figures are below the typical thresholds for strong performance in the Commodity Chemicals industry, where ROE and ROA are often higher due to the capital-intensive nature of the sector. The operating margin, calculated as operating income of INR 21,295,890 on revenue of INR 113,580,090, is approximately 18.75%, which is in line with the industry's median but does not indicate a competitive advantage. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's revenue concentration in a single segment and geographic area is a notable risk factor, especially in a volatile industry like Commodity Chemicals. Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, with a slight increase expected in the following year. However, the capital expenditure of INR -116,390,350 indicates a significant outflow of cash, which may impact future growth and operational flexibility. The company's growth trajectory is constrained by its high debt load and limited liquidity, which may limit its ability to invest in new projects or expand operations. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position and high debt-to-equity ratio suggest that the company may face challenges in meeting its short-term obligations without additional financing. However, the low dilution risk indicates that the company is not expected to issue a large number of new shares in the near term, which is a positive sign for existing shareholders. Recent filings and transcripts do not indicate any major strategic shifts or significant operational changes. The company's management has not disclosed any plans for restructuring or major capital raising activities, which suggests a stable but conservative approach to business operations. The absence of recent major events or announcements implies that the company is maintaining the status quo, which may be appropriate given its current financial position.

30-day price · RAAJ+19.01 (+26.8%)
Low$70.99High$91.99Close$90.00As of17 May, 00:00 UTC
Profile
CompanyRaaj Medisafe India Ltd
TickerRAAJ.BO
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Raaj Medisafe India Ltd is a chemical manufacturing company that produces commodity chemicals and generates revenue primarily through the sale of chemical products to industrial and consumer markets.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a confidence level of 0.92 based on verified market data.

Raaj Medisafe India Ltd has a debt-to-equity ratio of 2.39, indicating a capital structure that is heavily leveraged relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.16, suggesting it has just enough current assets to cover its current liabilities. However, the company's cash and equivalents amount to only INR 321,130, which is significantly lower than its long-term debt of INR 259,263,440, resulting in a negative net cash position. The company's profitability metrics show a return on equity (ROE) of 6.45% and a return on assets (ROA) of 1.69%. These figures are below the typical thresholds for strong performance in the Commodity Chemicals industry, where ROE and ROA are often higher due to the capital-intensive nature of the sector. The operating margin, calculated as operating income of INR 21,295,890 on revenue of INR 113,580,090, is approximately 18.75%, which is in line with the industry's median but does not indicate a competitive advantage. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The company's revenue concentration in a single segment and geographic area is a notable risk factor, especially in a volatile industry like Commodity Chemicals. Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, with a slight increase expected in the following year. However, the capital expenditure of INR -116,390,350 indicates a significant outflow of cash, which may impact future growth and operational flexibility. The company's growth trajectory is constrained by its high debt load and limited liquidity, which may limit its ability to invest in new projects or expand operations. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position and high debt-to-equity ratio suggest that the company may face challenges in meeting its short-term obligations without additional financing. However, the low dilution risk indicates that the company is not expected to issue a large number of new shares in the near term, which is a positive sign for existing shareholders. Recent filings and transcripts do not indicate any major strategic shifts or significant operational changes. The company's management has not disclosed any plans for restructuring or major capital raising activities, which suggests a stable but conservative approach to business operations. The absence of recent major events or announcements implies that the company is maintaining the status quo, which may be appropriate given its current financial position.
Key takeaways
  • The company has a high debt-to-equity ratio of 2.39, indicating a capital structure that is heavily leveraged.
  • Raaj Medisafe India Ltd's ROE of 6.45% and ROA of 1.69% are below typical industry benchmarks for strong performance.
  • The company's revenue is concentrated in a single business segment and geographic area, increasing exposure to regional risks.
  • The company's growth is constrained by high debt and limited liquidity, with a capital expenditure of INR -116,390,350.
  • The company faces medium liquidity risk but has low dilution risk, suggesting a stable capital structure in the near term.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$113.6M
Gross profit$43.8M
Operating income$21.3M
Net income$7.0M
R&D
SG&A
D&A
SBC
Operating cash flow$42.7M
CapEx-$116.4M
Free cash flow
Total assets$412.9M
Total liabilities$304.5M
Total equity$108.4M
Cash & equivalents$321.1k
Long-term debt$259.3M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$318.1M$33.6M$23.0M-$8.8M
FY-3$346.9M$45.2M$30.1M$25.3M
FY-2$386.2M$48.8M$33.3M$23.6M
FY-1$432.5M$58.5M$33.3M-$74.7M
FY0$624.2M$73.8M$61.3M-$71.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$166.1M$10.7M$148.7k
FY-3$196.2M$41.5M$190.2k
FY-2$257.7M$74.9M$132.4k
FY-1$412.9M$108.4M$321.1k
FY0$692.2M$269.2M$516.1k
PeriodOCFCapExFCFSBC
FY-4$22.3M-$38.9M-$8.8M
FY-3$24.5M-$12.1M$25.3M
FY-2$1.7M-$17.3M$23.6M
FY-1$42.7M-$116.4M-$74.7M
FY0-$868.3k-$147.1M-$71.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$113.6M$21.3M$7.0M
FQ-6$109.1M$15.1M$9.7M
FQ-5$109.1M$15.1M$9.7M
FQ-4$145.9M$18.1M$10.3M
FQ-3$244.0M$27.8M$34.8M
FQ-2$158.3M$21.4M$14.6M
FQ-1$184.0M$25.5M$17.3M
FQ0$207.1M$32.3M$18.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$412.9M$108.4M$321.1k
FQ-6
FQ-5$580.2M$224.7M$1.5M
FQ-4
FQ-3$692.2M$269.2M$516.1k
FQ-2
FQ-1$891.4M$291.1M$2.3M
FQ0
PeriodOCFCapExFCFSBC
FQ-7$42.7M-$116.4M
FQ-6
FQ-5-$18.0M-$82.9M
FQ-4
FQ-3-$868.3k-$147.1M
FQ-2
FQ-1$9.6M-$138.9M
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$108.4M
Net cash-$258.9M
Current ratio1.2
Debt/Equity2.4
ROA1.7%
ROE6.5%
Cash conversion6.1%
CapEx/Revenue-1.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricRAAJActivity
Op margin18.7%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin6.2%4.1% medp25 0.1% · p75 8.8%above median
Gross margin38.6%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-102.5%-6.2% medp25 -13.4% · p75 -2.6%bottom quartile
Debt / equity239.0%37.1% medp25 10.3% · p75 82.0%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:10 UTC#8ab700f4
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 03:27 UTCJob: beb93799